In that regard, primarily assessing total ALP activity as an initial assessment is appropriate and sufficient to identify putative HPP patients since the disease-causing ALPL gene constitutes the genetic background for all bone and liver isoforms of the enzyme, which normally account for > 90% of circulating ALP activity [1, 37]. This evidence concerns the gene ALPL and hypophosphatasia.